Multiple Sclerosis and Related Disorders

Papers
(The TQCC of Multiple Sclerosis and Related Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study91
Involvement Peripheral Nerve System in Multiple Sclerosis66
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease55
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets52
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study52
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia50
Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum49
Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects44
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)43
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy43
Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran42
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography40
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review40
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul39
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis39
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study37
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis37
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients37
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports36
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis36
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects36
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis34
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry34
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis33
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study33
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review33
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya33
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis32
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS32
Autoimmune encephalitis: A retrospective monocentric experience32
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk32
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease32
How Much Is Enough? Determining Minimum Valid Tracking Periods for Reliable Physical Activity Monitoring32
Sexual problems in MS: Sex differences and their impact on quality of life32
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination32
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod32
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis31
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan31
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis31
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series30
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study30
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis30
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?30
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial30
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina30
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis29
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies29
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?29
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors29
Sarcopenia in patients with multiple sclerosis29
Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis29
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study28
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America28
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience28
Impact of insurance status on MRI phenotypes in MS28
Diagnosing ‘transition’ to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians27
Lipid measures are associated with cognitive functioning in multiple sclerosis patients27
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal27
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis27
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran26
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis26
What telomeres teach us about MS25
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life25
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression25
Dietary intake and characteristics in persons with multiple sclerosis25
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis25
Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment24
41. Neuropathic Pain in Multiple Sclerosis24
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort24
30. Thalamic Volume Differentiates Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorder24
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms24
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents24
23. Vanishing Clues: A Systematic Review of Oligoclonal Band Disappearance in Multiple Sclerosis Patients after Treatment23
70. Real-World Experience of Cladribine Tablets in the Treatment of Multiple Sclerosis: An Omani Cohort from Khoula Hospital23
67. Domain-Specific and Global Cognitive Impairment in Multiple Sclerosis Patients Based on Cambridge Neuropsychological Test Automated Battery23
95. Patterns of Corpus Callosum Lesions in Demyelinating Diseases of the Central Nervous System23
165. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab23
120. The Pathological Findings of the First Cervical Spine MRI of The Neuromyelitis Optica Spectrum Disorders Patients23
81. Gender Difference In Egyptian Patients With Multiple Sclerosis23
101. Pseudotumor Demyelinating Lesions in Inflammatory Diseases of the Central Nervous System: An Algerian Series23
RETRACTED: New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-1922
Cross-Cultural Adaptation and Psychometric Evaluation of the Physical Activity and Disability Survey - Revised in People with Multiple Sclerosis22
134. Impact of Bowel Dysfunction, Urinary Dysfunction, and Fatigue on Quality of Life in Multiple Sclerosis22
Dysphagia in Relation with Depression, Anxiety, Fatigue, Sleep Quality, and Pain in Multiple Sclerosis22
Efficacy of Virtual Reality Interventions on Mood and Cognition in Patients with Multiple Sclerosis. a Systematic Review22
Bio-Psycho-Social Model of Multiple Sclerosis (BPSMMS)22
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool22
Adherence to Treatment in Multiple Sclerosis22
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters22
Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography21
Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging21
Effects of submotor-threshold tibial nerve stimulation on plantarflexion torque in healthy adults and people with multiple sclerosis21
Carotid intima media thickness and multiple sclerosis21
Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study21
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study21
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study21
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications21
Patients experiences when receiving diagnosis of multiple sclerosis: A qualitative systematic review20
Using MS induced pluripotent stem cells to investigate MS aetiology20
Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study20
The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis20
Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study20
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model20
The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia20
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial20
Vascular endothelial dysfunction associated with severity in multiple sclerosis20
Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study20
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up20
Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey20
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting mul20
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database19
Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis19
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis19
Telehealth in Multiple Sclerosis: Fostering Quality of Life19
Exclusion of alternative diagnoses: A component of the 2023 MOGAD criteria that belongs at the forefront, not in the background19
Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis19
Defining the prodromal phase of multiple sclerosis based on healthcare access in a Portuguese population - ProdMS study19
Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management19
Cardiovascular risk estimated in individuals with multiple sclerosis: A case-control study19
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis19
Predictors of Progression of Multiple Sclerosis in a Sample of Egyptian Patients19
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies19
Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey18
Multiple Sclerosis in Elderly Patients: When We Can Stopped Treatment?18
An internet-based survey of synesthesia in multiple sclerosis: Incidence, characteristics and implications18
Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls18
Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort18
Barriers to Engage in Physical Activity in People with Multiple Sclerosis in Jordan18
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS18
Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD18
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology18
The Effect of Rituximab on Mood Disorders in Multiple Sclerosis18
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group18
Depression, Anxiety and Alexithymia in Tunisian Patients with Multiple Sclerosis18
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study18
Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study18
Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study18
Real World Study of Ocrelizumab in Multiple Sclerosis: Kuwait Experience18
Perspectives on fatigue management among veterans living with multiple sclerosis18
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD18
Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis18
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)18
Monkeypox in Multiple Sclerosis patients: Should we be alert?18
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina17
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis17
Burden of multiple sclerosis: impact on the patient, family and society17
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study17
Impact of multiple sclerosis on male sexual and reproductive health17
Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study17
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis17
Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on the balance and the white matter integrity in patients with relapsing-remitting multiple sclerosis: A long-term follow-u17
Capacity of fullerenols to modulate neurodegeneration induced by ferroptosis: Focus on multiple sclerosis17
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial17
Evaluating the impact of systematic reporting of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a randomized controlled trial17
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients17
Cervical lymph node diameter reflects disease progression in multiple sclerosis17
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review17
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review17
Higher frequency of Human herpesvirus-6 (HHV-6) viral DNA simultaneously with low frequency of Epstein-Barr virus (EBV) viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil17
Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study17
Factors contributing to falls in people with multiple sclerosis: The exploration of the moderation and mediation effects17
The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis17
Cerebrospinal fluid indices as predictors of treatment response in autoimmune encephalitis17
Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm17
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers17
Sleep, physical activity, and psychological outcomes in children and adolescents with pediatric onset multiple sclerosis16
The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis16
Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka16
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab16
Validity and reliability of the Six-Minute Pegboard Ring Test for assessing functional capacity and upper limb function in persons with multiple sclerosis16
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison16
Range of motion abnormalities in the lower limb joints during gait in youth with multiple sclerosis16
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care16
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis16
Neural Substrates of Mobility and Postural Impairments in People with Multiple Sclerosis16
Mitochondrial Mutations in Multiple Sclerosis Patients with Atypical Optic Neuropathy16
COVID-19 in neuromyelitis optica spectrum disorder patients in Poland16
Optical coherence tomography and visual evoked potential and its relationship with neurological disability in patients with relapsing-remitting multiple sclerosis16
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal16
Psychotherapy and professional psychological support in multiple sclerosis: Uncovering patients’ patterns of access and preferences16
Social network size and mental health outcomes in youth with neuroinflammatory disorders16
MS in the UAE: Population Estimates of Anxiety, Depression and Health-Related Quality of Life15
Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach15
Multiple Sclerosis and biological definitions in neurodegenerative diseases15
124. The Prevalence of Iron Overload in Patients with Multiple Sclerosis in National Guard Health Affair Hospital, Riyadh Center from 2015-202115
Beyond the B-cell as a treatment target in multiple sclerosis15
Quality of life, Knowledge and Access to Treatment in Times of Economic crisis in Lebanon15
Prevalence of Urinary Tract Symptoms in Patients with Multiple Sclerosis and Health Care Seeking Behavior: A Cross Sectional Study in Riyadh, Saudi Arabia.15
Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience15
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)15
High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study15
MRI-based radiomics for differention of aquaporin 4-immunoglobulin G–positive neuromyelitis optic spectrum disorder and anti myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder15
Serum Neurofilament Light Chain as a Biomarker of Disease Progression in a Sample of Egyptian Multiple Sclerosis Patients15
106. Assessment of Depression and Anxiety in Patients with Multiple Sclerosis in Morocco15
Prognosis of walking function in multiple sclerosis supported by gait pattern analysis15
Linking X to MS: Immunity and demyelination on the X-chromosome in MS15
Clinical Characteristics of Switching Between Disease Modifying Drugs Among a Sample of Egyptian Multiple Sclerosis Patients15
Emerging trends in multiple sclerosis research15
Multiple Sclerosis in Middle East North Africa (MENA) Region: Challenges, Achievements and Opportunities.15
Serum Oxidative Stress Biomarkers in Relapsing Remitting Multiple Sclerosis Patients with No Evidence of Disease Activity15
Seizures in inflammatory demyelinating disorders of the central nervous system15
79. Sustained Treatment Persistence and High Adherence to Cladribine Tablets in Multiple Sclerosis: Results from Patient Support Program in Gulf Countries15
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy15
Aggressive Pediatric Multiple Sclerosis: Features and therapeutic Challenges15
Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response15
The prevalence of Myocardial Infarction among Multiple Sclerosis Patients: a Systematic Review and Meta-analysis15
Effects of Cognitive and Motor Secondary Tasks on Gait Performance in Healthy Controls and Multiple Sclerosis Patients with and Without Fall History15
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis15
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes14
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies14
Comparison of vision-related quality of life in NMOSD and MOGAD14
Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes14
S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th14
Allied health professionals knowledge and clinical practice in telehealth exercise behavioural change for multiple sclerosis14
Unwrapping the “black box” of balance training in people with multiple sclerosis – A descriptive systematic review of intervention components, progression, and intensity14
Deciphering the bidirectional impact of leukocyte telomere length on multiple sclerosis progression: A Mendelian randomization study14
Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy14
Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disorders14
Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection14
MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis14
Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity14
Self-reported fatigue impact is associated with frequency of falls and injurious falls in people with multiple sclerosis14
Association between clinical characteristics, acute steroid treatment and oligoclonal bands result in multiple sclerosis: A retrospective study14
Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis14
Reduced physical activity in multiple sclerosis: The role of gait parameters, gait variability parameters and self-reported measure of gait14
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants14
Coenzyme Q10 supplementation in multiple sclerosis; A systematic review14
Bone loss and fracture in people with multiple sclerosis: A systematic review and meta-analysis14
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis14
Consultation in Patients with Multiple Sclerosis13
Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap in Patient with Multiple Sclerosis Treated with Ocrelizumab: A Case Study and Literature Review13
44. Breaking Free from the Six-Month Cycle13
Cognitive Impairment in Multiple Sclerosis: the Role of Sleep Disorders13
Possible Markers of Venous Sinus Pressure Elevation in Multiple Sclerosis: Correlations with Gender and Disease Progression13
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis13
The Impact of Bladder Dysfunction on Physical Activity in Multiple Sclerosis Using Wearable Technology13
Weak grip strength among persons with multiple sclerosis having minimal disability is not related to agility or integrity of the corticospinal tract13
What If It Is not Optic Neuritis?13
31. Quantitative susceptibility mapping (QSM)-based regional iron concentration: Does it correlate with brain volume loss? An analysis of 250 regions of interest (ROIs)13
The Association of ApoE Genotype and Cognitive Impairment in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis13
Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection13
Multiple sclerosis-related heat sensitivity linked to absence of DMT prescription and subjective hand impairment but not autonomic or corticospinal dysfunction13
Optic Nerve Imaging Solving Demyelination Mystery13
Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain13
Mitochondrial DNA Copy Number as a Biomarker of Multiple Sclerosis13
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS13
Revolutionizing MS Care and Research: Inside Iran's Nationwide Multiple Sclerosis Registry13
148. Correlations Between Cognitive Impairment and Multiple Sclerosis Treatments13
Comparing traditional modeling approaches versus predictive analytics methods for predicting multiple sclerosis relapse13
Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments13
0.13240909576416